Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib DDI Study in Cancer Patients
NCT02688088Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in cancer and metastatic cancer (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration (Cmax) of Caffeine at Day 8, Maximum Concentration (Cmax) of S-Warfarin at Day 8 and 6 more. Started Mar 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
cancermetastatic cancer
Beyond the preview
Go deeper on NCT02688088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02688088.